New Cancer Target May Spare Healthy Tissue
Early lab work suggests a selective way to block WNT signaling in tumors that have lost a specific gene, a route that has not yet been tested in patients.
Updated on Nov. 2, 2026 in Cancer

Weill Cornell Medicine researchers identified a genetic vulnerability that may allow WNT signaling to be targeted in cancer more selectively. The team's experimental compound, TDI-012804, inhibited the enzyme TNKS2 in laboratory models and spared cells with normal TNKS1 levels, a possible route toward fewer side effects for future cancer drugs.
Why it matters
WNT signaling is overactive in nearly all colorectal cancers and many breast, lung, liver, and prostate tumors, but past attempts to block it have damaged healthy intestine and bone tissue. A way to act only where cancer cells have lost TNKS1 could, if it holds up, address one of the main obstacles to WNT-targeted treatment.
The findings come from laboratory experiments and three-dimensional organoid models carrying cancer-associated mutations, published in Nature Chemical Biology. The results are preclinical, so they do not yet show effects in patients.
The players
Weill Cornell Medicine
A New York City academic medical center whose researchers conduct cancer biology and drug discovery studies.
The details
Researchers used computational modeling and structural analysis to find a subtle difference in a flexible region of TNKS2. Many cancers lose a region of chromosome 8 that contains the gene TNKS1, and cancer cells that lose TNKS1 become increasingly dependent on TNKS2 to keep WNT signaling running. Because TDI-012804 targets TNKS2 far more strongly than TNKS1, it can shut down WNT signaling in those cells while leaving cells with normal TNKS1 levels largely untouched.
Timeline
Findings published online in Nature Chemical Biology on 2026-11-02.
Health Landscape
Blocking WNT signaling has long been a sought-after cancer strategy, but earlier inhibitors have been constrained by toxicity to normal intestinal and bone tissue. This finding points toward a selectivity approach that exploits a genetic difference between tumor cells and healthy cells, though it remains at the laboratory stage.
For people with colorectal, breast, lung, liver, or prostate cancer, this is early research rather than a new treatment option. If you have questions about how cancer pathways are targeted in current care, they are worth raising with your oncologist.
The takeaway
This is an early laboratory step toward cancer drugs that might spare healthy tissue, not a therapy available today. Anyone with questions about WNT-pathway treatments should ask their oncology team what options are currently appropriate.
Further reading
Explore more Cancer coverage for context on how researchers are approaching tumor biology and treatment.
Source note: This article includes information reported by Inside Precision Medicine.





